Back to news FoRx Therapeutics AG appoints Ulrich Lücking as Head of Chemistry Basel, Switzerland, 01 June, 2020 – FoRx Therapeutics, a recently incorporated privately-held company developing first-in-class compounds for cancer treatment, today announces the...
Back to news FoRx Therapeutics AG Raises EUR 10 Million Seed Round First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer Seasoned Biotech Executive Colin Goddard Joins as Executive Chairman Basel, Switzerland, 22 April, 2020 – FoRx...
